Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30-positive Lymphoma”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Testing effectiveness (Phase 2)Study completedNCT02280785
What this trial is testing

Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas

Who this might be right for
Non-Hodgkin Lymphoma
Samsung Medical Center 33
Not applicableNo Longer AvailableNCT01196208
What this trial is testing

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin+1 more
Seagen Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07717580
What this trial is testing

Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)

Who this might be right for
Cutaneous T-Cell Lymphoma/Mycosis FungoidesPrimary Cutaneous Anaplastic Large Cell Lymphoma
Peking University First Hospital 46
Testing effectiveness (Phase 2)Ended earlyNCT02594163
What this trial is testing

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryFollicular B-cell Non-Hodgkin's Lymphoma
Seagen Inc. 25
Testing effectiveness (Phase 2)Study completedNCT02939014
What this trial is testing

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Who this might be right for
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Takeda 39
Very early researchLooking for participantsNCT07048353
What this trial is testing

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Who this might be right for
LymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd 15
Not applicableLooking for participantsNCT07074457
What this trial is testing

Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

Who this might be right for
CD30+ Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University 47
Not applicableLooking for participantsNCT05481437
What this trial is testing

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Takeda 8
Not applicableStudy completedNCT03729609
What this trial is testing

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Who this might be right for
Untreated CD30-Positive Hodgkin's Lymphoma
Takeda 113
Not applicableLooking for participantsNCT07624838
What this trial is testing

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Who this might be right for
CD30-Positive Peripheral T-Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 100
Testing effectiveness (Phase 2)WithdrawnNCT02729961
What this trial is testing

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveCD30-Positive Neoplastic Cells PresentSystemic Anaplastic Large Cell Lymphoma
University of Washington
Testing effectiveness (Phase 2)WithdrawnNCT04334174
What this trial is testing

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

Who this might be right for
T Cell Lymphoma
University of Kansas Medical Center
Early research (Phase 1)Ended earlyNCT00649584
What this trial is testing

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 44
Early research (Phase 1)Study completedNCT02822586
What this trial is testing

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Who this might be right for
Mycosis FungoidesSézary Syndrome
Virginia Commonwealth University 5
Post-approval studies (Phase 4)Study completedNCT05442554
What this trial is testing

Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Who this might be right for
T-Cell Lymphoma
Takeda 10
Not applicableStudy completedNCT05506774
What this trial is testing

People With CD30 Positive Lymphoma in China

Who this might be right for
Lymphoma
Takeda 1,006
Not applicableStudy completedNCT04213209
What this trial is testing

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Who this might be right for
Peripheral T Cell LymphomaPediatric Hodgkin Lymphoma
Takeda 95
Early research (Phase 1)Study completedNCT01026415
What this trial is testing

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Who this might be right for
CarcinomasDisease, HodgkinLymphoma, Large-Cell, Anaplastic+2 more
Seagen Inc. 73
Testing effectiveness (Phase 2)Active Not RecruitingNCT06550336
What this trial is testing

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

Who this might be right for
Peripheral T Cell Lymphoma
The First Hospital of Jilin University 35
Testing effectiveness (Phase 2)Study completedNCT04074746
What this trial is testing

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
M.D. Anderson Cancer Center 45
Next Page